Kathleen Ann Cooney, MD

Professor of Medicine
George Barth Geller Distinguished Professor of Medicine
Chair, Department of Medicine
Member of the Duke Cancer Institute
Campus mail 2301 Erwin Road, Duke Hospital North Suite 1102, Durham, NC 27710
Phone (919) 681-2452
Email address kathleen.cooney@duke.edu

Dr. Cooney is Chair of the Duke Department of Medicine.

She is a medical oncologist focused in caring for men with prostate cancer, and is internationally known for her investigations focused on the genetic epidemiology of prostate cancer.

Her research led to the important discovery of a recurrent mutation in the HOXB13 gene that increases the chances of being diagnosed with prostate cancer and is estimated to account for 5 percent of hereditary prostate cancer cases worldwide. Since men with HOXB13 mutations are at an increased risk of prostate cancer, they may benefit from participation in screening and potentially prevention protocols in the future.

Dr. Cooney’s research continues with federal funding to identify germline mutations associated with lethal and aggressive prostate cancer as well as prostate cancer in African American men.

Education and Training

  • Fellow, Hematology / Oncology, University of Michigan, Ann Arbor, 1988 - 1991
  • Chief Medical Resident, Internal Medicine, University of Michigan, Ann Arbor, 1987 - 1988
  • Intern/Resident, Internal Medicine, University of Michigan, Ann Arbor, 1984 - 1987
  • M.D., University of Pennsylvania, School of Medicine, 1984

Publications

Beebe-Dimmer, Jennifer L., Kimberly A. Zuhlke, Anna M. Johnson, Daniel Liesman, and Kathleen A. Cooney. “Rare germline mutations in African American men diagnosed with early-onset prostate cancer.” Prostate 78, no. 5 (April 2018): 321–26. https://doi.org/10.1002/pros.23464.

PMID
29356034
Full Text

Giri, Veda N., Karen E. Knudsen, William K. Kelly, Wassim Abida, Gerald L. Andriole, Chris H. Bangma, Justin E. Bekelman, et al. “Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 4 (February 2018): 414–24. https://doi.org/10.1200/jco.2017.74.1173.

PMID
29236593
Full Text

Chen, Haitao, Charles M. Ewing, Sigun Zheng, Eli M. Grindedaal, Kathleen A. Cooney, Kathleen Wiley, Srdjan Djurovic, et al. “Genetic factors influencing prostate cancer risk in Norwegian men.” Prostate 78, no. 3 (February 2018): 186–92. https://doi.org/10.1002/pros.23453.

PMID
29181843
Full Text

Cooney, Kathleen A. “Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact.” Trans Am Clin Climatol Assoc 128 (2017): 14–23.

PMID
28790484
Scholars@Duke

Jackson, William C., Felix Y. Feng, Stephanie Daignault, Maha Hussain, David Smith, Kathleen Cooney, Kenneth Pienta, et al. “A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy.” Adv Radiat Oncol 1, no. 1 (January 2016): 59–66. https://doi.org/10.1016/j.adro.2015.11.001.

PMID
28799570
Full Text

Helfand, Brian T., Kimberly A. Roehl, Phillip R. Cooper, Barry B. McGuire, Liesel M. Fitzgerald, Geraldine Cancel-Tassin, Jean-Nicolas Cornu, et al. “Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.” Hum Genet 134, no. 4 (April 2015): 439–50. https://doi.org/10.1007/s00439-015-1534-9.

PMID
25715684
Full Text

Lange, EM, Johnson, AM, Wang, Y, Zuhlke, KA, Lu, Y, Ribado, JV, Keele, GR, Li, J, Duan, Q, Li, G, Gao, Z, Li, Y, Xu, J, Isaacs, WB, Zheng, S, and Cooney, KA. "Genome-wide association scan for variants associated with early-onset prostate cancer." Plos One 9, no. 4 (April 16, 2014).

Full Text

Bradley, D. A., S. Daignault, C. J. Ryan, R. S. DiPaola, K. A. Cooney, D. C. Smith, E. Small, et al. “Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8).” Investigational New Drugs 29, no. 6 (December 1, 2011): 1517–18. https://doi.org/10.1007/s10637-010-9502-7.

Full Text

Bradley, Deborah A., Stephanie Daignault, Charles J. Ryan, Robert S. Dipaola, Kathleen A. Cooney, David C. Smith, Eric Small, et al. “Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.” Invest New Drugs 29, no. 6 (December 2011): 1432–40. https://doi.org/10.1007/s10637-010-9420-8.

PMID
20336348
Full Text

Pages